Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants

Journal of Paediatrics and Child Health

Volumn 38, Issue 6, 2002, Pages 550-554

  Vogel, A M ^a,e   Lennon, D R ^b   Broadbent, R ^c   Byrnes, C A ^d   Grimwood, K ^b,d   Mildenhall, L ^c   Richardson, V ^c,d   Rowley, S ^c,d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Ornithological Society of New Zealand   (New Zealand)

^c Fetus and Newborn Committee   (New Zealand)

^d Paediatric Society of New Zealand   (New Zealand)

^e South Auckland Health   (New Zealand)

Author keywords

Consensus; Cost effectiveness; Palivizumab; Preterm; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; GESTATIONAL AGE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFANT DISEASE; INFECTION PREVENTION; INFECTION RISK; NEW ZEALAND; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; NEW ZEALAND; PATIENT READMISSION; PREMEDICATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS;

EID: 0036433434     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1754.2002.00057.x     Document Type: Article

References (23)

1. Impact Respiratory Syncytial Virus Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-7.
2. American Academy of Pediatrics. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102: 1211-16.
3. Joint statement of the Canadian Paediatric Society and the Fetus and Newborn Committee. Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory virus infection in high risk infants. J. Paediatr. Child Health 1999; 4: 474-80.
4. Lee SL, Robinson JL. Questions about palivizumab (Synagis). Pediatrics 1999; 103: 535.
5. Moler FW. RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure? Pediatrics 1999; 104: 559-60.
6. Sharland M, Bedford-Russell A. Preventing respiratory syncytial virus bronchiolitis. Br. Med. J. 2001; 322: 62-3.
7. Hall CB, Stevens TP, Swantz RJ, Sinkin RA, McBride JT. Development of local guidelines for prevention of respiratory syncytial viral infections. Pediatr. Infect. Dis. J. 1999; 18: 850-3.
8. Vogel A, Lennon D, Harding J. Trends in bronchiolitis admissions in New Zealand. Proceedings of the Paediatric Society of New Zealand; November 2000; Hawkes Bay, New Zealand. Paediatric Society of New Zealand, Wellington, 2000.
9. Grant CC, Scragg R, Tan D, Pati A, Aickin R, Yee RL. Hospitalization for pneumonia in children in Auckland, New Zealand. J. Paediatr. Child Health 1998; 34: 355-9.
10. Vogel AM, McKinlay MJ, Ashton T et al. Cost-effectiveness of palivizumab in New Zealand. J. Paediatr. Child Health 2002; 38: 352-7.
11. Poets CF. When do infants need additional inspired oxygen? A review of the current literature. Pediatr. Pulmonol. 1998; 26: 424-8.
12. Abbott UK. UK Guidance for the Use of Synagis. Abbott Laboratories, Berkshire, UK, 1999.
13. Carbonell-Estrany X, Guiffre L, Kimpen JLLet al. Guidelines for the use of Synagis (palivizumab), a humanised monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) disease in high risk infants: A consensus opinion. Infect. Med. (Suppl.) 1999; 16: 29-33.
14. Azar P, Broglia B, Miceli NPet al. Guidelines for the use of palivizumab in the prevention of RSV disease: A consensus opinion. Pediatr. Rev. En Espanol 2000; 21: 62-8.
15. Joffe S, Escobar GJ, Black SB, Armstrong MA, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 1999; 104: 894-9.
16. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999; 104: 419-27.
17. Numa A. Outcome of respiratory syncytial virus infection and a cost benefit analysis of prophylaxis. J. Paediatr. Child Health 2001; 36: 422-7.
18. Lenney W. Palivizumab and RSV prevention. Arch. Dis. Child. 2000; 83: 87.
19. Meissner HC, Welliver RC, Chartrand SA et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: A consensus opinion. Pediatr. Infect. Dis. J. 1999; 18: 223-3.
20. Sorrentino M, Powers T, Palivizumab Outcomes Study Group. Effectiveness of palivizumab: Evaluation of outcomes from the 1998-99 respiratory syncytial virus season. Pediatr. Infect. Dis. J. 2000; 19: 1068-71.
21. Sanchez PJ. Immunoprophylaxis of respiratory syncytial virus disease. Pediatr. Infect. Dis. J. 2000; 19: 791-801.
22. Atkins JT, Karimi P, Morris BH, McDavid G, Shim S. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less. Reduction in incidence, severity of illness and cost. Pediatr. Infect. Dis. J. 2000; 19: 138-43.
23. Dougherty NC, Meissner HC. Respiratory syncytial virus immunoprophylaxis. Impact on epidemiology. Pediatr. Drugs 2001; 2: 127-32.